Ratings by Jefferies (Amin Makarem)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/10/2026 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2026 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2026 | UroGen Pharma | URGN | New Coverage | Buy (N/A) |
19.10 (34.04) |
78.22% | Details | |
| 3/12/2026 | Foghorn Therapeutics | FHTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2026 | Foghorn Therapeutics | FHTX | New Coverage | Buy (N/A) |
5.26 (2.05) |
-61.03% | Details | |
| 2/17/2026 | Cellectis | CLLS | New Coverage | Buy (N/A) |
3.49 (0.97) |
-72.21% | Details |
